HIV-1 Drug Resistance Emergence among Breastfeeding Infants Born to HIV-Infected Mothers during a Single-Arm Trial of Triple-Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission: A Secondary Analysis

English version České info

Background:
Nevirapine and lamivudine given to mothers are transmitted to infants via breastfeeding in quantities sufficient to have biologic effects on the virus; this may lead to an increased risk of a breastfed infant's development of resistance to maternal antiretrovirals. The Kisumu Breastfeeding Study (KiBS), a single-arm open-label prevention of mother-to-child HIV transmission (PMTCT) trial, assessed the safety and efficacy of zidovudine, lamivudine, and either nevirapine or nelfinavir given to HIV-infected women from 34 wk gestation through 6 mo of breastfeeding. Here, we present findings from a KiBS trial secondary analysis that evaluated the emergence of maternal ARV-associated resistance among 32 HIV-infected breastfed infants.

Methods and Findings:
All infants in the cohort were tested for HIV infection using DNA PCR at multiple study visits during the 24 mo of the study, and plasma RNA viral load for all HIV-PCR–positive infants was evaluated retrospectively. Specimens from mothers and infants with viral load >1,000 copies/ml were tested for HIV drug resistance mutations. Overall, 32 infants were HIV infected by 24 mo of age, and of this group, 24 (75%) infants were HIV infected by 6 mo of age. Of the 24 infants infected by 6 mo, nine were born to mothers on a nelfinavir-based regimen, whereas the remaining 15 were born to mothers on a nevirapine-based regimen. All infants were also given single-dose nevirapine within 48 hours of birth. We detected genotypic resistance mutations in none of eight infants who were HIV-PCR positive by 2 wk of age (specimens from six infants were not amplifiable), for 30% (6/20) at 6 wk, 63% (14/22) positive at 14 wk, and 67% (16/24) at 6 mo post partum. Among the 16 infants with resistance mutations by 6 mo post partum, the common mutations were M184V and K103N, conferring resistance to lamivudine and nevirapine, respectively. Genotypic resistance was detected among 9/9 (100%) and 7/15 (47%) infected infants whose mothers were on nelfinavir and nevirapine, respectively. No mutations were detected among the eight infants infected after the breastfeeding period (age 6 mo).

Conclusions:
Emergence of HIV drug resistance mutations in HIV-infected infants occurred between 2 wk and 6 mo post partum, most likely because of exposure to maternal ARV drugs through breast milk. Our findings may impact the choice of regimen for ARV treatment of HIV-infected breastfeeding mothers and their infected infants.

Trial Registration: ClinicalTrials.gov NCT00146380

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: HIV-1 Drug Resistance Emergence among Breastfeeding Infants Born to HIV-Infected Mothers during a Single-Arm Trial of Triple-Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission: A Secondary Analysis. PLoS Med 8(3): e32767. doi:10.1371/journal.pmed.1000430
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000430

Souhrn

Zdroje

1. UNAIDS 2008 Report on the global AIDS epidemic. UNAIDS 2008. Available: http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/globalreport/2008/jc1511_gr08_executivesummary_en.pdf. Accessed 26 February 2011

2. HarambatJ

FassinouP

BecquetR

ToureP

RouetF

2008 18-month occurrence of severe events among early diagnosed HIV-infected children before antiretroviral therapy in Abidjan, Cote d'Ivoire: a cohort study. BMC Public Health 8 169

3. DabisF

EkpiniER

2002 HIV-1/AIDS and maternal and child health in Africa. Lancet 359 2097 2104

4. WiktorSZ

EkpiniE

KaronJM

NkengasongJ

MauriceC

1999 Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 353 781 785

5. JacksonJB

MusokeP

FlemingT

GuayLA

BagendaD

2003 Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362 859 868

6. UNICEF 2005 Unite for children, unite against AIDS campaign. Available: http://www.unicef.org/aids/index.html. Accessed 26 February 2011

7. HeinigMJ

2002 Breastfeeding decisions. Pediatrics 110 1033 1034

8. HeinigMJ

2001 Host defense benefits of breastfeeding for the infant. Effect of breastfeeding duration and exclusivity. Pediatr Clin North Am 48 105 123

9. HeinigMJ

1998 The American Academy of Pediatrics recommendations on breastfeeding and the use of human milk. J Hum Lact 14 2 3

10. Nommsen-RiversL

HeinigMJ

1997 HIV transmission via breastfeeding: reflections on the issues. J Hum Lact 13 179 181

11. MoodleyD

MoodleyJ

CoovadiaH

GrayG

McIntyreJ

2003 A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 187 725 735

12. MirochnickM

SiminskiS

FentonT

LugoM

SullivanJL

2001 Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 20 803 805

13. MirochnickM

ThomasT

CapparelliE

ZehC

HollandD

2009 Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 53 1170 1176

14. ThomasT

MasabaR

NdivoR

ZehC

BorkowfC

2011 Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding—The Kisumu Breastfeeding Study, Kenya: A Clinical Trial. PLoS Med 8 e1001015 doi:10.1371/journal.pmed.1001015

15. World Health Organization 2003 Scaling up antiretroviral therapy in resource-limited settings. Treatment guidelines for a public health approach Geneva WHO

16. MofensonLM

McIntyreJA

2000 Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 355 2237 2244

17. DorenbaumA

CunninghamCK

GelberRD

CulnaneM

MofensonL

2002 Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 288 189 198

18. United States Food and Drug Administration 2005 Public health advisory for nevirapine (Viramune). Available: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051674.htm. Accessed 26 February 2011

19. JohnsonVA

Brun-VezinetF

ClotetB

GunthardHF

KuritzkesDR

2008 Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med 16 62 68

20. SwoffordDL

2001 PAUP: Phylogenetic analysis using parsimony, version 4. Sunderland (Massachusetts) Sinauer

21. LidstromJ

GuayLA

MusokeP

OworM

Onyango-MakumbiC

2010 Multi-class drug resistance arises frequently in hiv-infected breastfeeding infants whose mothers initiate highly active antitetroviral therapy (HAART) post-partum [Abstract]. The 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco (California, United States) 433

22. EshlemanSH

MracnaM

GuayLA

DeseyveM

CunninghamS

2001 Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15 1951 1957

23. World Health Organization 2007 HIV transmission through breastfeeding; a review of available evidence; an update from 2001 to 2007. Available: http://whqlibdoc.who.int/publications/2008/9789241596596_eng.pdf. Accessed 26 February 2011

24. ViolariA

CottonMF

GibbDM

BabikerAG

SteynJ

2008 Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 359 2233 2244

25. CorbettA

MartinsonF

RezkN

KashubaA

JamiesonD

2008 Antiretroviral drug concentrations in breastmilk and breastfeeding infants. The 15th Conference on Retroviruses and Opportunistic Infections; 3–6 February 2008; Boston (Massachusetts, United States) CROI 2008

26. KumwendaNI

HooverDR

MofensonLM

ThigpenMC

KafulafulaG

2008 Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 359 119 129

27. MoorthyA

GuptaA

SastryJ

VenkatramaniV

BbosaleR

2008 Timing of infection is critical for nevirapine resistance outcomes among breastfed subtype C HIV-1 infected infants exposed to extended vs single-dose NVP prophylaxis: The India SWEN Study [Abstract 44, 86 2008]. The 15th Conference on Retroviruses and Opportunistic Infections; 3–6 February 2008; Boston (Massachusetts, United States)

28. ChurchJD

OmerSB

GuayLA

HuangW

LidstromJ

2008 Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis 198 1075 1082

29. ColebundersR

HodossyB

BurgerD

DaemsT

RoelensK

2005 The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS 19 1912 1915

30. YangC

LiM

ShiYP

WinterJ

van EijkAM

2004 Genetic diversity and high proportion of intersubtype recombinants among HIV type 1-infected pregnant women in Kisumu, western Kenya. AIDS Res Hum Retroviruses 20 565 574

31. World Health Organization 2007 HIV and Infant feeding Update. Available: http://whqlibdoc.who.int/publications/2007/9789241595964_eng.pdf. Accessed 28 February 2011